Insulin regulates the expression of more than 150 genes, indicating that this is a major action of this hormone.
Introduction
Insulin regulates metabolism by altering the quantities of critical proteins and by altering the activity or location of pre-existing enzyme molecules. T h e mechanisms through which insulin mediates the latter effects have been studied extensively for many years [l-31. Similarly, over the past 10 years there have also been considerable advances in the understanding of several aspects of insulin-regulated gene expression [4, 5] .
Insulin has been shown to regulate the expression of specific genes by affecting transcription, mRNA stability or mRNA translation [4,5]. Little is known about the regulation of mRNA Table I Comparison of consensus IRSs
The identification ofthe various lRSs shown is described in [5,T] . Abbreviations: Apo, apolipoprotein; AP-I, activator protein I ; FAS, fatty acid synthase: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SREBP, sterol-response-element-binding protein; TAT, tyrosine aminotransferase; T F -2 , thyroid transcription factor.
I RS type Genes
Effect This article focuses on the analysis of the promoter elements, transcription factors and the signalling pathway through which insulin inhibits transcription of the gene encoding the G6Pase catalytic subunit.
[111.
The GdPase system
G6Pase is located in the endoplasmic reticulum (ER) and catalyses the terminal step of the glycogenolytic pathway in liver and the gluconeogenic pathway in liver and kidney. T h e enzyme is thought to exist as a multisubunit system; however, the exact number of components, their stoichiometry and their topological relationships are unclear [17,18]. On the basis of studies with microsomes, it was concluded that the G6Pase catalytic subunit, which spans the ER membrane multiple times, has its catalytic site oriented towards the ER lumen [17,18]. A model was therefore proposed in which the G6Pase catalytic subunit was postulated to be associated functionally with transporters for glucose 6-phosphate, Pi and glucose that serve to deliver cytosolically generated glucose 6-phosphate to the active site and shuttle the reaction products back to the cytosol [17,18]. In contrast, data derived from rapid kinetic studies favour an alternative model that places the active site of the G6Pase catalytic subunit within the membrane and predicts that the catalytic subunit has both a catalytic activity and a transport function [17, 18] .
Inactivating mutations within the G6Pase catalytic subunit cause glycogen storage disease type la, which is characterized principally by severe hypoglycaemia in the post-absorptive state [19] . In contrast, elevated G6Pase activity contributes to the increased hepatic production of glucose and the hyperglycaemia that characterizes diabetes [20, 21] .
GdPase catalytic subunit insulin response unit (IRU)
Studies in liver in vivo and studies in liver-derived cell lines or in primary hepatocytes in situ have shown that glucose, glucocorticoids, CAMP, fatty acids, leptin and p3 adrenergic receptor agonists all stimulate the expression of the gene encoding the G6Pase catalytic subunit [22-281, whereas insulin inhibits both the basal expression of the gene encoding the G6Pase catalytic subunit and overrides the stimulatory effects of glucose, glucocorticoids, cAMP and fatty acids [22] [23] [24] 26, 28] .
T o study the molecular mechanism by which insulin inhibits transcription of the gene encoding the G6Pase catalytic subunit, the gene encoding the mouse G6Pase catalytic subunit was isolated and various fragments of the promoter were ligated into the pCAT(An) expression vector (in which CAT stands for chloramphenicol acetyltransferase) [ 141. The resulting fusion gene constructs were then analysed through transient transfection of the human HepG2 and rat H4IIE cell lines [14-161. The hormonal regulation of a fusion gene construct containing mouse G6Pase catalytic subunit sequence between -75 1 and +66 mimics that of the gene encoding the endogenous G6Pase catalytic subunit in HepG2 and H4IIE cells in that cAMP and the synthetic glucocorticoid dexamethasone stimulate G6Pase-CAT fusion gene expression but these effects are blocked by insulin [14, 29] . Insulin also inhibits the basal expression of this G6Pase-CAT fusion gene [14] as it does basal expression of the gene encoding the endogenous G6Pase catalytic subunit in hepatoma cells [29] . This latter observation is significant because experiments on the gene encoding phosphoenolpyruvate carboxykinase (PEPCK) have shown that, in contrast, insulin represses only CAMP-and dexamethasone-stimulated, but not basal, PEPCK-CAT fusion gene expression after either transient [14] or stable [30] 0 2001 Biochemical Society transfection. As a consequence, the identification of one or more IRSs in the PEPCK promoter has proved to be a difficult problem [S] . This is because of the need to elevate basal PEPCK-CAT expression, using dexamethasone or CAMP, to be able to study the negative effect of insulin [S] . The potential co-localization of positive promoter elements required for the stimulatory effects of dexamethasone and/or cAMP with the negative promoter elements required for the effect of insulin has made the interpretation of such experiments difficult [S] . Thus it has proved difficult to mutate specific promoter elements selectively to disable the negative action of insulin while leaving intact the stimulatory effects of dexamethasone and/or cAMP [S] . We therefore made use of the observation that insulin inhibits basal G6Pase-CAT fusion gene expression to define the regions of the promoter required for this action of insulin.
Deletion of the G6Pase catalytic-subunit promoter sequence between -231 and -199 (designated region A) partly decreased the inhibitory effect of insulin, whereas deletion of an additional sequence between -198 and -159 (designated region B) almost completely abolished the remaining effect of insulin on G6Pase-CAT fusion gene expression [ 14,151 (Figure 1 ). The simplest interpretations of these results were that either (1) regions A and B each contain an independent IRS or (2) only region B contains an IRS, whereas region A acts as an accessory element that enhances the action of a single IRS located in region B. T o distinguish between these possibilities, doublestranded oligonucleotides representing either region A or region B were synthesized and ligated into the BamHI site of a heterologous vector designated TKC-VI. This vector contains the thymidine kinase (TK) promoter ligated to the CAT reporter gene and had previously been used to define an inhibitory IRS in the PEPCK promoter [31] . Insulin had little effect on CAT expression directed by the basic TKC-VI vector; however, ligation of region B, but not region A, into the BamHI site of TKC-VI conferred an insulin-dependent, orientation-independent, inhibition of CAT expression after transient transfection of H4IIE cells [14, 15] . We therefore proposed a model in which the transcription factor binding to region A acts as an accessory factor to enhance the effect of insulin that is mediated through the transcription factor binding to the IRS in region B ( Figure 1B) . Together, regions A and B form an IRU. Such hormone response units are commonly found to mediate the actions of CAMP and glucocorticoids on gene transcription but this arrangement is unusual with regard to insulin action on gene transcription [5] .
T h e transcription factor that binds region A and enhances insulin signalling through the IRS in region B was found to be hepatocyte nuclear factor 1 (HNF-I) [15] . T h e model in Figure 1(B) indicates that HNF-1 directly contacts the insulinresponsive factor (IRF) binding to the IRS in region B but it is equally possible that HNF-1 contacts the basal transcriptional machinery and has a structural role in maintaining some specific architectural aspect of the G6Pase catalytic-sub- The identity of the I R F binding to region B has been elusive. Region B actually contains three sequences, each of which matches the IRSs identified in the PEPCK, insulin-like-growthfactor-binding protein 1 (IGFBP-I), tyrosine aminotransferase and apolipoprotein CI I I gene promoters (Table 1 and Figure 2) . As with the gene encoding the G6Pase catalytic subunit, insulin also inhibits the transcription of these other genes. Several proteins have been identified that bind promoter elements that encompass this consensus IRS, including members of the C/EBP (CCAAT-enhancer-binding protein) [32] , HNF-3 [33, 34] and F K H R (forkhead in rhabdomyosarcoma) families of transcription factors [16, it seems that in no case is the binding of one of these proteins clearly correlated with the effect of insulin [37] . Clearly, the identification of the genuine I R F is of major interest, particularly because this protein represents a prime therapeutic target : compounds that mimic the action of insulin on this protein would be predicted to decrease the elevated rate of hepatic glucose production seen in diabetics (see above).
Because the PEPCK, IGFBP-1, tyrosine aminotransferase, apolipoprotein CI I I and G6Pase catalytic subunit IRSs all share the same consensus (Table l) , it has been assumed that the same trans-acting factor mediates the effect of insulin on the transcription of all of these genes. However, we have recently begun comparing the effect of mutating the IGFBP-1 and G6Pase
HNF-6-binding site is located 3' of the CRE. catalytic subunit IRSs on basal gene expression; the results suggest that these IRSs might be functionally distinct. Thus a mutation of the IGFBP-1 IRS results in a decrease in basal gene expression, whereas mutation of the three G6Pase catalytic subunit IRSs in region B does not (results not shown). Our working hypothesis is that the IGFBP-1 IRS binds an activator, such as F K H R [36] , whereas the G6Pase catalytic subunit IRSs bind both an activator and repressor ( Figure  2B ). Mutation of the three G6Pase catalytic subunit IRSs in region B would therefore result in a loss of both repressor and activator binding such that there would be no net change in basal gene expression ( Figure 2B ). We have also found that FKHR binds the three IRSs in region B with different affinities (results not shown), an observation that is probably explained by the fact that these three IRSs have slightly different sequences ( Figure 2A ). Our working model therefore also envisages that the putative activator and repressor selectively bind individual IRSs in region B ( Figure 2B ). Another key question that remains unresolved is how insulin blocks the stimulatory effects of cAMP and glucocorticoids on transcription of the gene encoding the G6Pase catalytic subunit. T h e region B IRSs in the G6Pase catalytic subunit promoter are co-localized with a putative glucocorticoid response element (GRE) [38] . They are therefore potentially ideally positioned to mediate the inhibitory action of insulin on glucocorticoid-stimulated G6Pase catalytic subunit gene transcription. However, additional upstream promoter elements are required for the full stimulatory effect of glucocorticoids on transcription of the gene encoding the G6Pase catalytic subunit ( [38] , and R. S. Streeper and R. M. O'Brien, unpublished work) . Thus the stimulatory effect of glucocorticoids on G6Pase catalytic-subunit gene transcription is mediated through a complex glucocorticoid response unit. Whether these upstream elements are independent GREs or accessory elements that enhance the activity of the region B G R E remains to be determined. Interestingly, Chou and colleagues [38] have shown that HNF-1 acts as an accessory factor to enhance the stimulatory effect of glucocorticoids on transcription of the gene encoding the G6Pase catalytic subunit, just as it does the inhibitory effect of insulin (see above).
How insulin blocks the stimulatory effect of cAMP on G6Pase catalytic subunit gene transcription is harder to envisage. Multiple cis-acting elements in the G6Pase promoter are required for the full stimulatory effect of the cAMP signaltransduction pathway on G6Pase catalytic subunit gene expression that together comprise a cAMP response unit (CRU) [21, 3941] . At least two of these elements, a CRE and an HNF-6 motif (Figure 1 B) bind transcription factors, namely CRE-binding protein (CREB) and HNF-6, that are phosphorylated by the catalytic subunit of protein kinase A [41] . However, most of the elements that comprise the CRU are located 3' of the IRU ; the exception is the CREB-binding site that partly overlaps the most proximal IRS in region B (Figures 1B and 2A) . Thus, in contrast with the glucocorticoid response unit, the potential for direct insulin-dependent interference between elements of the CRU and IRU is less apparent. However, Schmoll et al. [42] have recently reported the existence of an IRU-independent pathway that operates through a proximal region of the promoter and could potentially interfere with the CRU.
Insulin signalling to the G6Pase catalytic subunit IRU
Whereas the elucidation of insulin signalling pathways has progressed markedly, a complete signalling pathway, from insulin receptor to transcription factor, involved in the regulation of a metabolically important gene has yet to be clearly established. T h e available results suggest that distinct insulin signalling pathways regulate the expression of distinct genes [S] . T h e pathway(s) through which insulin suppresses gene transcription through the PEPCK-like IRS (Table 1) have been the most closely investigated. Insulin inhibits transcription of the genes encoding PEPCK, IGFBP-1 and the G6Pase catalytic subunit through the same phosphoinositide-3-kinase-dependent pathway, independently of the activation of p70" 6k and mitogen-activated protein kinase [4346] . However, the downstream target of phosphoinositide 3-kinase activation is the subject of conflicting reports : several groups postulate that protein kinase B (PKB) mediates the effect of insulin on these genes [42, 45, 47] , whereas several other groups report that PKB is not required [44, 46, 48] . Some of these conflicting results might be explained by the fact that these groups have studied the effect of expressing various forms of PKB on basal, glucocorticoidstimulated or CAMP-stimulated gene expression. However, the mechanism of insulin action in suppressing the basal transcription of these genes 
